Nucana Plc Quick Ratio (NCNA) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Nucana Plc  (NASDAQ: NCNA)

Nucana Plc's Quick Ratio

NCNA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 5.06 below Nucana Plc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 128 other companies have achieved higher Quick Ratio than Nucana Plc in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 410, from total ranking in the third quarter 2025 at 1593.

Explain Quick Ratio?
How much Cash & cash equivalents NCNA´s has?
What are NCNA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

NCNA Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -40.6 % -40.6 % -40.6 % -40.6 % -32.83 %
Y / Y Cash & cash equivalent Change 129.61 % 146.28 % 146.28 % 146.28 % -50.13 %
Quick Ratio MRQ 5.06 5.43 5.43 5.43 1.31
NCNA's Total Ranking # 410 # 1593 # # #
Seq. Current Liabilities Change -0 % 0 % 0 % -40.6 % -0 %
Seq. Cash & cash equivalent Change -6.77 % 0 % 0 % 146.28 % -0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 129
Healthcare Sector # 204
Overall Market # 410


Quick Ratio Statistics
High Average Low
16.1 6.92 1.31
(Sep 30 2018)   (Dec 31 2024)




Financial Statements
Nucana Plc's Current Liabilities $ 6 Millions Visit NCNA's Balance sheet
Nucana Plc's Cash & cash equivalent $ 33 Millions Visit NCNA's Balance sheet
Source of NCNA's Sales Visit NCNA's Sales by Geography


Cumulative Nucana Plc's Quick Ratio

NCNA's Quick Ratio for the trailling 12 Months

NCNA Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -40.6 % -38.02 % -35.95 % -30.15 % -29.01 %
Y / Y Cash & cash equivalent TTM Growth 142.11 % 67.6 % 15.23 % -17.03 % -47.29 %
Quick Ratio TTM 5.34 3.95 2.84 1.99 1.31
Total Ranking TTM # 2454 # 3606 # # #
Seq. Current Liabilities TTM Growth -14.59 % -12.74 % -11.3 % -10.15 % -10.89 %
Seq. Cash & cash equivalent TTM Growth 15.45 % 21.12 % 26.78 % 36.57 % -20.08 %

Quick ratio ranking by company, industry and sector >> Back to NCNA Financial Strength Comparisons >> Go to Compare NCNA Quick Ratio to its Competitors

On the trailing twelve months basis NCNA Cash & cash equivalent more than doubled by 129.61 % in Q4 2025 year on year, while Current Liabilities remained unchanged to $6 millions, this led to increase in in Nucana Plc's Quick Ratio to 5.34, Quick Ratio remained below NCNA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 281 other companies have achieved higher Quick Ratio than Nucana Plc. While Quick Ratio overall ranking has improved so far to 2454, from total ranking during the twelve months ending third quarter 2025 at 3606.

Explain Quick Ratio?
How much Cash & cash equivalents NCNA´s has?
What are NCNA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 282
Healthcare Sector # 595
Within the Market # 2454


trailing twelve months Quick Ratio Statistics
High Average Low
14.6 8.26 1.76
(Dec 31 2018)   (Dec 31 2023)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Oric Pharmaceuticals Inc   13.79 $ 281.488  Millions$ 20.417  Millions
Vtv Therapeutics Inc   13.39 $ 88.932  Millions$ 6.641  Millions
Agios Pharmaceuticals Inc   13.39 $ 854.425  Millions$ 63.814  Millions
Vera Therapeutics Inc   13.37 $ 714.589  Millions$ 53.455  Millions
Chemocentryx Inc.  13.22 $ 0.736  Millions$ 0.056  Millions
Dianthus Therapeutics Inc   13.16 $ 404.295  Millions$ 30.732  Millions
Rallybio Corporation  12.96 $ 54.736  Millions$ 4.223  Millions
Mirum Pharmaceuticals Inc   12.87 $ 732.452  Millions$ 56.890  Millions
Damora Therapeutics Inc   12.84 $ 257.624  Millions$ 20.066  Millions
Aptevo Therapeutics Inc   12.77 $ 42.119  Millions$ 3.298  Millions
Immuneering Corporation  12.77 $ 128.645  Millions$ 10.074  Millions
Harmony Biosciences Holdings inc   12.69 $ 775.340  Millions$ 61.093  Millions
Chemomab Therapeutics Ltd   12.61 $ 10.366  Millions$ 0.822  Millions
Protagonist Therapeutics inc   12.49 $ 567.364  Millions$ 45.441  Millions
Pulmatrix Inc   12.43 $ 4.088  Millions$ 0.329  Millions
Bridgebio Oncology Therapeutics Inc   12.14 $ 425.460  Millions$ 35.041  Millions
Vyne Therapeutics Inc   12.11 $ 29.008  Millions$ 2.395  Millions
Crinetics Pharmaceuticals Inc   12.08 $ 1,027.889  Millions$ 85.072  Millions
Arrivent Biopharma inc   12.06 $ 312.821  Millions$ 25.931  Millions
Kailera Therapeutics Inc   12.04 $ 546.056  Millions$ 45.365  Millions
Diamedica Therapeutics Inc   11.93 $ 59.890  Millions$ 5.020  Millions
Silo Pharma Inc  11.86 $ 6.859  Millions$ 0.578  Millions
Crescent Biopharma Inc   11.85 $ 213.192  Millions$ 17.997  Millions
Equillium Inc   11.78 $ 30.277  Millions$ 2.571  Millions
Pepgen Inc   11.74 $ 148.456  Millions$ 12.646  Millions
Canton Strategic Holdings Inc   11.68 $ 12.007  Millions$ 1.028  Millions
Pliant Therapeutics Inc   11.67 $ 190.944  Millions$ 16.365  Millions
Savara Inc   11.56 $ 235.702  Millions$ 20.396  Millions
Anixa Biosciences Inc   11.49 $ 14.202  Millions$ 1.236  Millions
Mineralys Therapeutics Inc   11.44 $ 172.921  Millions$ 15.113  Millions

Date modified: 2026-09-09T12:37:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.